Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.77 which represents a decrease of $-0.40 or -1.53% from the prior close of $26.17. The stock opened at $26.16 and touched a low ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...